EMAIL US AT info@bcan.org
SUPPORT HOTLINE 888-901-2226
Donate Now

All Posts by Stephanie Chisolm

Approval For The First-Ever Targeted Therapy For Metastatic Bladder Cancer

Janessen has announced its drug  BALVERSA or erdafitinib has received accelerated approval from the FDA “for the treatment of adults with locally advanced or metastatic urothelial carcinoma.” Stephanie Chisolm, PhD, BCAN’s Director of Education and Research said, “This new treatment option is wonderful news for patients with metastatic bladder cancer. We

Read More

2019 BCAN Think Tank – Advancing Bladder Cancer Research

The 2019 Bladder Cancer Think Tank August 8 – 10, 2019 | Washington, DC The Think Tank is the premier annual bladder cancer-specific medical meeting in North America and BCAN’s essential vehicle for advancing collaborative bladder cancer research efforts. Since its inception in 2006, this scientific meeting has focused on identifying obstacles

Read More

KU Bladder Cancer – What you should know.

Saturday, May 18, 2019 | 10:00 AM- 2:00 PM Location: 2146 West 39th Avenue, Kansas City, KS 66103 |Room HEB B102 This free patient and caregiver program is brought to you by the University of Kansas Urology Department and the Bladder Cancer Advocacy Network Program Agenda 10:00am – 10:05am | Introduction to Symposium

Read More

BCAN 2019 Patient-Centered Clinical Research Young Investigator Award

BCAN is pleased to announce the offering of one 2019 Patient-Centered Clinical Research Young Investigator Award. This $50,000 one  year Award is intended to support the development of outstanding research scientists and clinical cancer research investigators who have demonstrated a commitment to improving the understanding, treatment, and experience of bladder cancer.  Investigators

Read More

BCAN 2019 Young Investigator Award

BCAN is pleased to announce the offering of two 2019 Young Investigator Awards. This $50,000 one year award is intended to support the development of outstanding research scientists and clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of bladder cancer.  Investigators may be working in

Read More